68Gallium–Prostate-Specific Membrane Antigen PET/Computed Tomography for Primary and Secondary Staging in Prostate Cancer - 01/11/17
, Annika Herlemann, MD a, Melvin D'Anastasi, MD b, Clemens C. Cyran, MD b, Harun Ilhan, MD c, Christian Gratzke, MD a, d, Christian G. Stief, MD a, dRésumé |
Prostate-specific membrane antigen (PSMA) PET has been recently introduced for the diagnosis of patients with metastatic prostate cancer (PCa). Until today, staging of patients with PCa relied mostly on morphologic features, such as size or shape, resulting in low detection rates in disease recurrence. PSMA PET imaging provides molecular information and, in combination with conventional imaging, offers improved sensitivity and specificity. This review discusses the benefits and limitations of PSMA imaging in the setting of primary staging and detection of recurrent disease in comparison with standard-of-care imaging techniques.
Le texte complet de cet article est disponible en PDF.Keywords : Prostate cancer staging, PSMA, PET/CT, Biochemical recurrence
Plan
| Disclosure statement: The authors have nothing to disclose. |
Vol 44 - N° 4
P. 557-563 - novembre 2017 Retour au numéro
Article précédent
- Whom to Treat : Postdiagnostic Risk Assessment with Gleason Score, Risk Models, and Genomic Classifier
- Annika Herlemann, Samuel L. Washington, Renu S. Eapen, Matthew R. Cooperberg
- Contemporary Active Surveillance : Candidate Selection, Follow-up Tools, and Expected Outcomes
- Laurence Klotz
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?